Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly ' s Phase 3 Monotherapy Atopic Dermatitis Trials

New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity Results suggest less frequent, every four week...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials